The stipulated dismissal language is precise in its conditionality: the without-prejudice status is not permanent but instead functions as a 30-day grace period before automatic conversion to dismissal with prejudice. This structure is consistent with parties who have reached substantive agreement but require time to finalise documentation. Critically, neither party obtained any judicial ruling on the merits — no infringement finding, no invalidity determination, and no claim construction order is recorded. The each-party-bears-own-costs clause eliminates any § 285 exceptional-case fee exposure and is a standard feature of negotiated resolutions in complex medical device patent disputes.

Any company developing, manufacturing, or distributing Foley catheter insertion tray systems — including private-label hospital supply kits, CAUTI-reduction procedural trays, or integrated urological care bundles — should treat Medline’s four-patent portfolio as a live FTO concern. The dismissal without prejudice (and likely subsequent with-prejudice conversion) does not signal that Medline has abandoned enforcement; it signals that Bard resolved its exposure, likely commercially. New market entrants and existing tray suppliers have no judicial claim construction to rely on.

PatSnap Eureka’s FTO Search Agent can map the claim scope of US9808400B2, US9745088B2, US9795761B2, and US9808596B2 against your product specifications, identify design-around opportunities across the four application families, and surface any related continuation or divisional patents that may extend Medline’s coverage. Eureka also monitors PTAB proceedings linked to these application numbers, giving R&D and procurement teams real-time visibility into patent validity status before committing to product development or supplier agreements.